In the latest trading session, 0.45 million Anebulo Pharmaceuticals Inc (NASDAQ:ANEB) shares changed hands as the company’s beta touched -1.01. With the company’s most recent per share price at $0.95 changed hands at -$0.04 or -4.04% at last look, the market valuation stands at $21.97M. ANEB’s current price is a discount, trading about -247.37% off its 52-week high of $3.30. The share price had its 52-week low at $0.80, which suggests the last value was 15.79% up since then. When we look at Anebulo Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 31320.0 shares, with the 3-month average coming to 12.03K.
Analysts gave the Anebulo Pharmaceuticals Inc (ANEB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ANEB as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Anebulo Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.08.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Anebulo Pharmaceuticals Inc (NASDAQ:ANEB) trade information
Instantly ANEB was in red as seen in intraday trades today. With action -26.92%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -60.74%, with the 5-day performance at -26.92% in the red. However, in the 30-day time frame, Anebulo Pharmaceuticals Inc (NASDAQ:ANEB) is -36.67% down. Looking at the short shares, we see there were 10758.0 shares sold at short interest cover period of 1.94 days.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 84.17% from its recent market value. According to analyst projections, ANEB’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a -531.58% plunge from its current level, while the stock would need to soar -531.58% for it to hit the projected low.
Anebulo Pharmaceuticals Inc (ANEB) estimates and forecasts
Data shows that the Anebulo Pharmaceuticals Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -55.25% over the past 6 months, a -62.50% in annual growth rate that is considerably lower than the industry average of 17.20%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -155.95%. The 2024 estimates are for Anebulo Pharmaceuticals Inc earnings to decrease by -3.13%.
ANEB Dividends
Anebulo Pharmaceuticals Inc is expected to release its next quarterly earnings report in January.
Anebulo Pharmaceuticals Inc (NASDAQ:ANEB)’s Major holders
LVW ADVISORS, LLC holds the second largest percentage of outstanding shares, with 2.4757% or 0.64 million shares worth $1.75 million as of 2024-06-30.
